Operator-Led Innovation: A Venture Studio Approach to Accelerating Neuropsychiatric Drug Development
Time: 11:45 am
day: Day Two Track B - AM
Details:
- Negev Labs Managing Partner Shlomi Raz will introduce the firm’s operator-led venture studio model, designed to identify and advance neuropsychiatric drug candidates through a capital-efficient, milestone-driven approach.
- Shlomi will highlight Ariadne Bio, Negev Labs’ first portfolio company, which is developing a non-hallucinogenic 5-HT2A/2C agonist for apathy in Parkinson’s disease—an area of high unmet need—leveraging supportive human data.
- Dr. Dan Jeffries, Principal at Negev Labs, will then preview Athena Neuro, the studio’s next company launching later this year, focused on treating agitation in genetically defined neuropsychiatric populations through receptor subtype selectivity and translational biomarker strategies.
